Lumina Fund Management LLC continued to hold its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,500 shares of the company’s stock at the close of the second quarter. Teva Pharmaceutical Industries Limited makes up about 0.2% of Lumina Fund Management LLC’s portfolio, making the stock its 28th biggest holding. Lumina Fund Management LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $2,442,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. Comerica Bank grew its position in Teva Pharmaceutical Industries Limited by 21.3% in the 1st quarter. Comerica Bank now owns 102,913 shares of the company’s stock worth $3,265,000 after purchasing an additional 18,092 shares during the last quarter. Stevens Capital Management LP acquired a new stake in Teva Pharmaceutical Industries Limited in the 1st quarter worth $328,000. Benchmark Capital Advisors grew its position in Teva Pharmaceutical Industries Limited by 5.2% in the 1st quarter. Benchmark Capital Advisors now owns 32,244 shares of the company’s stock worth $1,035,000 after purchasing an additional 1,600 shares during the last quarter. Bronfman E.L. Rothschild L.P. grew its position in Teva Pharmaceutical Industries Limited by 7.8% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after purchasing an additional 261 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its position in Teva Pharmaceutical Industries Limited by 35.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 144,595 shares of the company’s stock worth $4,640,000 after purchasing an additional 37,692 shares during the last quarter. Institutional investors and hedge funds own 56.76% of the company’s stock.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 0.23% on Friday, reaching $17.19. 8,986,279 shares of the company were exchanged. The company’s market cap is $17.47 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $51.51. The company’s 50-day moving average price is $18.13 and its 200 day moving average price is $28.20.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.25 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were issued a $0.085 dividend. The ex-dividend date was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.98%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -15.36%.

TRADEMARK VIOLATION WARNING: “Lumina Fund Management LLC Has $2,442,000 Position in Teva Pharmaceutical Industries Limited (TEVA)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/24/lumina-fund-management-llc-has-2442000-position-in-teva-pharmaceutical-industries-limited-teva.html.

TEVA has been the topic of several research analyst reports. Mizuho upgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and raised their price target for the stock from $25.00 to $30.00 in a research report on Thursday, June 15th. Royal Bank Of Canada set a $38.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Friday, June 16th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, May 31st. Vetr downgraded shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $32.04 price objective for the company. in a report on Monday, June 5th. Finally, BidaskClub raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a report on Wednesday, July 5th. Five analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $30.91.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.